Cancer Research

We are proud to share that our team’s Liquid RNA abstract has been selected for presentation at the ESMO Targeted Anticancer Therapies Congress 2026! 

…And that our co-founder and CEO, Michelle Morand, will be representing Liquid Biopsy Labs at the ESMO Congress in Paris – and presenting our abstract on March 16th! 

ESMO Targeted Anticancer Therapies Congress

The ESMO Targeted Anticancer Therapies Congress brings together global leaders in oncology drug development and precision medicine. We are honored to contribute to this important scientific dialogue and to showcase the innovation behind our L-RNA platform.

If you are attending ESMO TAT 2026 in Paris, we would be honoured for you to visit our presentation and connect with us in person.

We look forward to meaningful conversations and new collaborations in Paris.

LRNA Abstract Presentation – Details

If you would like to attend, here are the details:

• Abstract: “Clinical Performance Of Novel Exosomal Liquid RNA Biopsy Assay In Lung Cancer Segment” 
• Presentation Number: 139P 
• Lecture Time: 17:30 – 17:30 
• Speakers: Michelle Morand (Vancouver, Canada) 
• Session Name: Poster Display session & networking reception 
• Location: Foyer, Palais des Congrès, Paris, France 
• Date: Mon, March 16, 2026 
• Time: 5:30pm to 6:30pm CET

→ See the full program
→ See the calendar listings

If you would like to meet with Michelle Morand during her stay in Paris, please email mmorand@liquidbiopsylabs.com or phone 778 990 4606.

Would you like to order or learn more about our groundbreaking LRNA test for early detection of cancer, diagnosis, and monitoring?

→ Learn more about the LRNA Liquid Biopsy

We hope to connect with you soon and support you with our expertise, testing options, and lab facilities.

Additional Publications

ASCO Presentation

In related news, we are also pleased to share that Liquid Biopsy Labs’ Liquid RNA abstract was selected for, and presented at, the American Society of Clinical Oncology GI 2026 conference in San Francisco, California, in January 2026. 

→ See the media presentation
→ See the abstract, ”Clinical performance of liquid RNA (L-RNA) biopsy in a gastrointestinal cancer segment.’’

If you would like to speak with co-founder and CEO of Liquid Biopsy Labs and CTOAM, Michelle Morand, you can reach her directly at mmorand@liquidbiopsylabs.com or join Michelle’s free Daily Drop-in Zoom Calls – Monday to Friday at 9:30am to 10:30am PT.

→ Join Michelle’s Free Daily Drop-in Zoom Calls